Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||IDH1 wild-type|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|IDH1 wild-type||high grade glioma||not applicable||N/A||Guideline||Risk Factor||IDH1 wild-type is associated with increased risk of aggressive disease in patients with grade II or III infiltrative gliomas (NCCN.org).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03018288||Phase II||Pembrolizumab + Temozolomide Pembrolizumab + Temozolomide + Vitespen||Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)||Recruiting|
|NCT04197934||Phase I||WSD0922||WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases||Recruiting|
|NCT04225039||Phase II||INCAGN01876 + Retifanlimab||Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma||Recruiting|
|NCT03896568||Phase I||DNX-2401||Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma||Recruiting|
|NCT01891747||Phase I||Bevacizumab + Temozolomide||A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma||Active, not recruiting|
|NCT03452930||Phase I||Tinostamustine||Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma||Recruiting|
|NCT03220646||Phase II||Abemaciclib||The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.||Recruiting|
|NCT03696355||Phase I||GDC-0084||Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas||Active, not recruiting|
|NCT03743662||Phase II||Nivolumab Bevacizumab||Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma||Recruiting|